| Followers | 14 |
| Posts | 1385 |
| Boards Moderated | 0 |
| Alias Born | 05/27/2011 |
Monday, August 23, 2021 7:37:27 AM
This petition request hit my email this morning, for a rare disease I'd never heard of - Niemann Pick Type C (NPC). We need a re-tooled FDA.
----------------------------------
(boldface mine)
We need your help to save our kids fighting fatal NPC.
We are patients and parents of children and adults living with an ultra-rare and fatal disease called Niemann Pick Type C (NPC). We are in a fight for our lives to get new therapies approved by the US FDA, and we need your help. The clock is ticking, and every day that goes by NPC is damaging us and our children.
NPC is like Alzheimers, Parkinson’s and ALS rolled into one, except even more rare, causing extreme declines in how we move, talk, think, and even eat - pretty much everything. This disease occurs across all ages - and, horrifically, will frequently first show up in young children, even babies.
There is no cure or approved therapy here in the United States...but there are several medicines that have been in development and used experimentally by patients for years and years. Patients AND our treating doctors see the tremendous benefits of these medicines in helping us keep the ability to walk, talk, play and swallow. This is a BIG deal. It’s life saving.
Heartbreakingly, however, the FDA has become a barrier to helping these therapies cross the finish line - requiring multiple placebo control trials, not listening to our expert clinicians, discounting patient benefits, and not understanding our ultra rare variable and fatal disease. And we have had enough. It is time for regulators to:
Think differently about treatments for NPC and the multiple clinical trials that have demonstrated how these therapies have benefits that outweigh their risks;
Listen to patients and families about their needs; and
Act on expert guidance from doctors and researchers across the country who have studied this disease and treated patients for decades and recommend approval of investigational therapies.
Our community has met many times with the decision makers at FDA over the years to discuss the desperate need for approved therapies - including as recently as August 3, 2021. And while government officials say they “hear us,” there is no sign of movement or action to advance our cause. In fact, FDA has tried to keep new patients from accessing these experimental medications by erecting hurdles to early access programs and denying requests for approvals.
We need the following changes to occur immediately:
The FDA must lift all barriers that have blocked new patients from participating in programs that allow access to experimental medications, or have created uncertainties for patients currently receiving these medications. This includes removing any barriers to receiving drugs known as adrabetadex and arimoclomol.
The FDA must evaluate medications to treat NPC with the knowledge that NPC is ultra-rare, degenerative and fatal, and use regulatory flexibility when reviewing clinical trial data that shows meaningful improvements, particularly given the known natural history of this fatal disease.
The FDA must work with the scientific and patient community to design trials that are feasible and meaningful and that the trials do not put patients in harm’s way.
Add your signature to tell the FDA that it must address the needs of those with NPC by approving medicines and increasing access to existing medicines. Please tell FDA, don’t give up on NPC - for the patients of tomorrow AND those alive today. Please help save our lives. Thank you!!
----------------------------------
(boldface mine)
We need your help to save our kids fighting fatal NPC.
We are patients and parents of children and adults living with an ultra-rare and fatal disease called Niemann Pick Type C (NPC). We are in a fight for our lives to get new therapies approved by the US FDA, and we need your help. The clock is ticking, and every day that goes by NPC is damaging us and our children.
NPC is like Alzheimers, Parkinson’s and ALS rolled into one, except even more rare, causing extreme declines in how we move, talk, think, and even eat - pretty much everything. This disease occurs across all ages - and, horrifically, will frequently first show up in young children, even babies.
There is no cure or approved therapy here in the United States...but there are several medicines that have been in development and used experimentally by patients for years and years. Patients AND our treating doctors see the tremendous benefits of these medicines in helping us keep the ability to walk, talk, play and swallow. This is a BIG deal. It’s life saving.
Heartbreakingly, however, the FDA has become a barrier to helping these therapies cross the finish line - requiring multiple placebo control trials, not listening to our expert clinicians, discounting patient benefits, and not understanding our ultra rare variable and fatal disease. And we have had enough. It is time for regulators to:
Think differently about treatments for NPC and the multiple clinical trials that have demonstrated how these therapies have benefits that outweigh their risks;
Listen to patients and families about their needs; and
Act on expert guidance from doctors and researchers across the country who have studied this disease and treated patients for decades and recommend approval of investigational therapies.
Our community has met many times with the decision makers at FDA over the years to discuss the desperate need for approved therapies - including as recently as August 3, 2021. And while government officials say they “hear us,” there is no sign of movement or action to advance our cause. In fact, FDA has tried to keep new patients from accessing these experimental medications by erecting hurdles to early access programs and denying requests for approvals.
We need the following changes to occur immediately:
The FDA must lift all barriers that have blocked new patients from participating in programs that allow access to experimental medications, or have created uncertainties for patients currently receiving these medications. This includes removing any barriers to receiving drugs known as adrabetadex and arimoclomol.
The FDA must evaluate medications to treat NPC with the knowledge that NPC is ultra-rare, degenerative and fatal, and use regulatory flexibility when reviewing clinical trial data that shows meaningful improvements, particularly given the known natural history of this fatal disease.
The FDA must work with the scientific and patient community to design trials that are feasible and meaningful and that the trials do not put patients in harm’s way.
Add your signature to tell the FDA that it must address the needs of those with NPC by approving medicines and increasing access to existing medicines. Please tell FDA, don’t give up on NPC - for the patients of tomorrow AND those alive today. Please help save our lives. Thank you!!
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
